Author information
1Center for Liver Diseases, E-Da Hospital, Kaohsiung, Taiwan. holdenhsu@gmail.com.
2School of Medicine, I-Shou University, Kaohsiung, Taiwan. holdenhsu@gmail.com.
3Division of Gastroenterology, Fu-Jen Catholic University Hospital, New Taipei, Taiwan. holdenhsu@gmail.com.
4Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, New Taipei, Taiwan. holdenhsu@gmail.com.
5Division of Gastroenterology and Hepatology, National University Health System, Singapore, Singapore.
6Department of Medicine, National University of Singapore, Singapore, Singapore.
7Department of Medicine, Stanford University Medical Centre, Palo Alto, CA, USA. mindiehn@stanford.edu.
8Department of Epidemiology and Population Health, Stanford University Medical Centre, Palo Alto, CA, USA. mindiehn@stanford.edu.
Abstract
Chronic hepatitis B virus (HBV) infection affects about 296 million people worldwide and is the leading aetiology of cirrhosis and liver cancer globally. Major medical complications also include acute flares and extrahepatic manifestations. In addition, people living with HBV infection also experience stigma. HBV-related cirrhosis resulted in an estimated 331,000 deaths in 2019, and it is estimated that the number of deaths from HBV-related liver cancer in 2019 was 192,000, an increase from 156,000 in 2010. Meanwhile, HBV remains severely underdiagnosed and effective measures that can prevent infection and disease progression are underutilized. Birth dose coverage for HBV vaccines remains low, particularly in low-income countries or regions where HBV burden is high. Patients with HBV infection are inadequately evaluated and linked to care and are undertreated worldwide, even in high-income countries or regions. Despite the goal of the World Health Organization to eliminate viral hepatitis as a public health problem by 2030, the annual global deaths from HBV are projected to increase by 39% from 2015 to 2030 if the status quo remains. In this Review, we discuss the current status and future projections of the global burden of HBV infection. We also discuss gaps in the current care cascade and propose future directions.